Can a gel coating stop infections after hip revision surgery?
NCT ID NCT05679232
First seen Oct 07, 2026 · Last updated Oct 08, 2026 · Updated 1 time
Summary
Researchers are testing a hydrogel coating called MectaShield that is applied to hip revision implants during surgery. The coating is designed to act as a barrier against bacteria that can cause joint infections. The trial compares two groups: one receives implants with the coating, and the other receives standard implants without it. The main goals are to check whether the coating affects how well the implant stays stable in the bone and to see if it reduces early infections.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a hydrogel coating applied to hip replacement implants
- What this could lead to
- If it works, the coating could offer a way to lower the risk of infection after revision hip surgery without changing the implant itself.
- What could go wrong
- This is a small, early feasibility study with 56 people at one hospital. The coating might not reduce infections, and it could interfere with how well the implant settles into the bone.
Why investors are watching
Medacta is testing MectaShield, a hydrogel coating applied to hip and cup implants during cementless revision hip arthroplasty, in a 56-person feasibility study that measures implant stability, infection rate, function, and adverse events against a control group. For a small-cap company, a clean result on safety and early performance would give it clinical evidence for a product line it sells, while a poor result would remove that support.
If it works: A positive readout may support further studies and give surgeons and buyers reason to adopt MectaShield as an infection-prevention option in revision hip surgery.
If it fails: The trial is small and early, so it may not show a clear benefit, and a safety signal or failure to meet its stability and infection goals may slow or stop the program.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 56 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2022
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Informed Consent signed by the subject * Males and females aged over 18 years at time of surgery * Subjects who are scheduled to receive a conical collarless cementless revision hip arthroplasty, with or without revision of the acetabular cup * Subjects willing to comply with the pre- and post-operative evaluation schedule Exclusion Criteria: * Subjects with one or more medical conditions identified as a contraindication defined by the labelling on any implants used in this study * Subjects with immune suppressive treatment for organ transplantation, or known allergy to MectaShield hydrogel constituents (Chitlac, Mannitol, Hydroxypropylmethylcellulose, Sodium phosphate dibasic) * Subjects presenting with progressive local or systemic infection at the time of surgery * Subjects whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems * Subjects affected by concomitant spine, hip, ankle or contralateral knee pathologies that can affect walking capacity * Subjects unable to understand and take action * Subjects undergoing cementless revision hip arthroplasty in emergency interventions
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Arthritis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Orthopädisches Spital Speising GmbH
RECRUITINGVienna, 1130, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Starving inflamed joints of blood: a new way to fight arthritis pain?
- Can a dual mobility hip implant outlast standard replacements?
- Hip implant under the microscope: can this cup stand the test of time?
- Hip implant under the microscope: how long does it last?
- Can this knee implant last a decade? study tracks outcomes
- Can a clinic tool get more arthritis patients moving?